BioAffinity Technologies' CyPath® Lung Tool Enhances Lung Cancer Detection for Veterans' Healthcare
- bioAffinity Technologies’ CyPath® Lung tool is now included in the Veterans Health Administration’s Federal Supply System for widespread access.
- The collaboration with VHA emphasizes partnerships to enhance healthcare solutions for veterans at higher lung cancer risk.
- bioAffinity aims to transform lung cancer detection and treatment through innovative diagnostics and public health commitment.
Innovative Lung Cancer Detection Tool Gains Traction in Veterans' Healthcare
bioAffinity Technologies, Inc., a biotechnology firm focused on noninvasive early-stage cancer detection, gains notable momentum with its CyPath® Lung diagnostic tool. This development comes as the Veterans Health Administration (VHA) includes CyPath® Lung in its Federal Supply System (FSS), granting access to a vast network of 1,380 healthcare facilities serving 9.1 million veterans annually. The tool's integration into the FSS enables bioAffinity to reach over 170 medical centers and more than 1,000 outpatient sites across the country, marking a significant milestone for the company and enhancing its visibility within the healthcare landscape.
Maria Zannes, President and CEO of bioAffinity Technologies, expresses appreciation for the role of the National Association of Veterans’ Research and Education Foundations (NAVREF) in raising awareness about CyPath® Lung among Veterans Affairs (VA) professionals and industry partners. This collaboration underscores the importance of partnerships in advancing healthcare solutions. Zannes highlights the critical role of the VA's National Acquisition Center, which facilitates access to innovative diagnostic tools, ultimately benefiting veterans who are at heightened risk for lung cancer. The VHA’s commitment to integrating such technologies indicates a shift towards more proactive healthcare measures for those who have served.
The partnership between bioAffinity and the VHA is emblematic of the broader trend towards public-private collaborations aimed at improving health outcomes for veterans. Rashi Romanoff, CEO of NAVREF, commends this alliance, noting that innovative diagnostic tools like CyPath® Lung can significantly enhance the care veterans receive. With veterans facing increased lung cancer risks due to age, smoking, and environmental exposures during military service, initiatives such as the Lung Precision Oncology Program aim to bolster detection and treatment efforts. Through these endeavors, bioAffinity Technologies positions itself as a key player in the evolving landscape of lung cancer diagnostics, promising to elevate the standard of care for veterans.
In addition to the integration of CyPath® Lung within the FSS, bioAffinity continues to engage with various stakeholders to promote its innovative diagnostic solutions. The emphasis on collaboration is crucial as the company seeks to navigate the complexities of the healthcare system and ensure that cutting-edge technologies reach those in need. As bioAffinity Technologies moves forward, the potential for its diagnostic tools to transform early detection and treatment for lung cancer remains promising.
The commitment to improving veteran healthcare through pioneering research and accessible clinical trials showcases bioAffinity’s dedication to public health. As the company presents its diagnostic tool at the upcoming NAVREF meeting, it sets the stage for further dialogue on enhancing the quality of care for veterans, fostering a future where early detection of lung cancer becomes a standard practice.